Establishing Novel Doxorubicin-Loaded Polysaccharide Hydrogel for Controlled Drug Delivery for Treatment of Pediatric Brain Tumors

Author:

Patel Jenny P.,Hendricks-Wenger AlissaORCID,Stewart Carli,Boone Kassidy,Futtrell-Peoples Naydia,Kennedy Lyndon,Barker Elizabeth D.ORCID

Abstract

AbstractAccording to the National Cancer Institute, of the more than 10 million cancer survivors alive in the United States at least 270,000 were originally diagnosed under the age of 21. While the 5-year survival rates for most childhood cancers appear very promising, the long-term survival rates are still very dismal. There is significant long-term morbidity and mortality associated with treatment of childhood cancer, and the risk of these effects continues to increase years after completion of therapy. Among childhood cancer survivors the cumulative incidence of a chronic health condition is 73.4% 30 years after the original cancer diagnosis, with a cumulative incidence of 42.4% for severe, disabling, life-threatening, or death due to a chronic condition caused by the chemotherapy used to treat the initial malignancy. Brain tumors are the most prevalent solid tumor diagnosed in children, and account for 20 percent of all childhood cancer deaths. The efficacy of all chemotherapy agents can be limited by their toxicity, their instability, and their ability to be formulated into practical drug products for use in the clinical setting To address this gap, our group has developed a novel carbohydrate-based hydrogel, Amygel, that is capable of being loaded with drugs and injected directly into the site of disease. Local drug delivery using Amygel has potential to improve childhood cancer treatment outcomes and prevent the devastating effects of systemic chemotherapy exposure. Development of Amygel for clinical use has three focus areas including: increasing drug concentration at the target site; improving chemotherapy penetration through tumor tissue, and; establishing chemotherapy dosage forms for pediatric use. For this study, we formulated Amygel with dimethyl sulfoxide and integrated the chemotherapy doxorubicin (DOX). High-performance liquid chromatography (HPLC) was used to confirm the quality of DOX after hydrogel synthesis, rheology and syringability tests to characterize the mechanical properties, and performed an in vitro cytotoxicity test against the pediatric medulloblastoma cell line DAOY. On HPLC, we found that after integrating DOX into the Amygel matrix the drug maintained a strong band on the chromatograph at the same point with the same intensity as the control free drug, indicating there were no changes in the structural properties of DOX. The mechanical tests showed that there was a proportionate increase in the storage modulus of the drug-loaded hydrogels as the concentration of amylopectin increased from 3 wt% to 20 wt%, but even at 20 wt% the hydrogel remained below the medical standard for injectables that the burst force should not exceed 40 N and the sliding force below 20 N. Correlating with the rheology findings, as the concentration of amylopectin increased, and therefore the strength of the hydrogel, there was an increase in the magnitude of force required for gel injection. These mechanical studies additionally provide evidence that the mechanical stability of the gel is not dampened by the incorporation of DOX. Drug release and cytotoxicity studies demonstrated a sufficient release of DOX from the hydrogels, and that the DOX released was able to achieve significant (p<0.01) cell death.

Publisher

Cold Spring Harbor Laboratory

Reference43 articles.

1. International incidence of childhood cancer, 2001–10: a population-based registry study

2. Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET)

3. Pediatric brain tumors;CONTINUUM: Lifelong Learning in Neurology,2020

4. Canadian pediatric neuro-oncology standards of practice;Frontiers in oncology,2020

5. Drug penetration in pediatric brain tumors: Challenges and opportunities;Pediatric Blood & Cancer,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3